License Agreements (Details)	Feb. 16, 2018 USD ($) product_formulation
Avadel Ireland \| LiquiTime Licensing and Development Agreement
Asset Acquisition And License Agreement [Line Items]
Number of product formulations \| product_formulation	4
Product royalty	6.00%
TRIS Pharma \| Karbinal Agreement
Asset Acquisition And License Agreement [Line Items]
Product royalty	23.50%
Contract term	20 years
Make whole payment, percent	8.50%
Potential milestone revenue threshold	$ 40,000,000
Potential milestone payment	$ 3,000,000
Eisai Inc \| AcipHex Agreement
Asset Acquisition And License Agreement [Line Items]
Product royalty	15.00%
Potential milestone revenue threshold	$ 50,000,000
Yung Shin Pharm. Ind, Co \| Cefaclor
Asset Acquisition And License Agreement [Line Items]
Product royalty	15.00%
Potential milestone revenue threshold	$ 40,000,000
Automatic renewal period	12 months
Maximum \| TRIS Pharma \| Karbinal Agreement
Asset Acquisition And License Agreement [Line Items]
Make whole payment	$ 750,000
Maximum \| Eisai Inc \| AcipHex Agreement
Asset Acquisition And License Agreement [Line Items]
Potential milestone payment	$ 8,000,000
Royalty payment period	5 years
Maximum \| Yung Shin Pharm. Ind, Co \| Cefaclor
Asset Acquisition And License Agreement [Line Items]
Potential milestone payment	$ 6,500,000